TNFSF10 and glioblastoma: As shown in Fig. 2a, H5CmTERT-Ad and H5CmTERT-Ad/TRAIL (P < 0.05, P < 0.01, or P < 0.001 versus Rb7Δ19 for U87MG, P < 0.01 or P < 0.001 versus Rb7Δ19 for U251N, respectively) had a dose-dependent cancer cell-killing effect that was superior to that of the Rb7Δ19 in glioblastoma cells.